Medicaid/CHIP providers who have not yet submitted their applications for federal Provider Relief Fund are encouraged to apply. The deadline is Sunday, Sept. 13, 2020.
Blog Entry List
NC Medicaid is temporarily increasing financial assistance to Federally Quality Health Centers (FQHCs) and Rural Health Centers (RHCs) to maintain critical access to care for Medicaid beneficiaries during the COVID-19 public health emergency.
NC-MIPS is Open for Program Year 2020, Program Year 2020 Webinar Series and The Security Risk Analysis (SRA)
This bulletin outlines the process by which nursing homes may access interim payments of State-administered federal funding to support compliance with Secretarial Order No.2.
NC Medicaid is reimbursing COVID-19 testing costs for individuals without insurance who enroll in the NC Medicaid Optional COVID-19 Testing (MCV) program.
Providers are required by State Health Director Order to report all results, positive and negative, of diagnostic testing for SARS-CoV-2, the virus that causes COVID-19.
NC Immunization Program/Vaccines for Children (NCIP/VFC), Billing/Reporting Influenza Vaccines for Medicaid Beneficiaries, Borrowing and Replacement of VFC and Private Vaccines, Borrowing and Replacement of VFC and Private Vaccines, Billing/Reporting Influenza Vaccines for NC Health Choice Beneficiaries, Immunization Billing for Medicaid and NC Health Choice Beneficiaries from FQHCs and RHCs and NDC’s Change Each Year for Influenza Vaccines.
The deadline for Medicaid/CHIP providers to submit their financial data to apply for federal provider relief funds has been extended to Sept. 13, 2020.
NC DHHS and the NC Area Health Education Center (AHEC) are partnering in a free webinar series offering guidance to dental professionals.
Effective with date of service June 17, 2020, the Medicaid and NC Health Choice programs cover mitomycin for pyelocalyceal solution (Jelmyto™) for use in the Physician Administered Drug Program (PADP) when billed with HCPCS code J9999 - Not otherwise classified, antineoplastic drugs.
Bimatoprost Implant, for Intracameral Administration (Durysta™) HCPCS Code J3490: Billing Guidelines
Effective with date of service June 26, 2020, the Medicaid and NC Health Choice programs cover bimatoprost implant, for intracameral administration (Durysta™) for use in the Physician Administered Drug Program (PADP) when billed with HCPCS code J3490 - Unclassified drugs.
Effective with date of service July 1, 2020, the Medicaid and NC Health Choice programs cover pertuzumab, trastuzumab, and hyaluronidase-zzxf injection, for subcutaneous use (Phesgo™) for use in the Physician Administered Drug Program (PADP) when billed with HCPCS code J9999 - Not otherwise classified, antineoplastic drugs.
Effective with date of service June 19, 2020, the Medicaid and NC Health Choice programs cover lurbinectedin for injection, for intravenous use (Zepzelca™) for use in the Physician Administered Drug Program (PADP) when billed with HCPCS code J9999 - Not otherwise classified, antineoplastic drugs.
A memo regarding North Carolina’s Design for State-Funded Services Under Behavioral Health and Intellectual/Developmental Disability Tailored Plans white paper has been released.
NC Medicaid is implementing additional rate increases to continue helping Local Health Departments (LHDs) to serve Medicaid beneficiaries during the COVID-19 public health emergency.